Volume 44, Issue 5 pp. 928-933
ORIGINAL ARTICLE

PCR-Fluo-ASXL1-FA: A fast, sensitive and inexpensive complementary method to detect ASXL1 mutations in haematological malignancies

Chloé Friedrich

Corresponding Author

Chloé Friedrich

Hematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), Paris, France

Correspondence

Chloé Friedrich, Hematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), 27 rue du Faubourg Saint-Jacques, 75014 Paris.

Email: [email protected]

Search for more papers by this author
Loria Zalmaï

Loria Zalmaï

Hematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), Paris, France

Search for more papers by this author
Juliette Gay

Juliette Gay

Hematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), Paris, France

Search for more papers by this author
Marie Magdeleine Coude

Marie Magdeleine Coude

Cerba Laboratory, Saint-Ouen-l'Aumône, France

Search for more papers by this author
Clotilde Bravetti

Clotilde Bravetti

Hematology Department, Hôpital de la Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France

Search for more papers by this author
Romain Vazquez

Romain Vazquez

Hematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), Paris, France

Search for more papers by this author
Marie Temple

Marie Temple

Hematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), Paris, France

Search for more papers by this author
Eugénie Duroyon

Eugénie Duroyon

Hematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), Paris, France

Search for more papers by this author
Luc Darnige

Luc Darnige

Hematology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), Paris, France

Search for more papers by this author
Justine Decroocq

Justine Decroocq

Clinical Hematology department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), Paris, France

Search for more papers by this author
Anne Sophie Alary

Anne Sophie Alary

Oncogenetic Department, Paoli-Calmette Institute, Marseille, France

Search for more papers by this author
Olivier Kosmider

Olivier Kosmider

Hematology Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris (APHP-CUP), Paris, France

Search for more papers by this author
First published: 06 July 2022

Abstract

Introduction

The additional sex combs like 1 (ASXL1) gene is frequently mutated in a number of haematological neoplasms. The c.1934dupG, known to be the most common alteration in ASXL1, is associated with poor clinical outcome. A systematic determination of ASXL1 mutational status in myeloid malignancies is therefore necessary for prognostic stratification.

Methods

Because direct sequencing is not sensitive and next-generation sequencing (NGS) is time-consuming, expensive and sometimes does not allow the detection of the c.1934dupG, we have developed a fragment analysis assay, complementary to NGS, that allows the detection of c.1934dupG mutation in addition to other nearby insertions/deletions of ASXL1 located close to it. We called this assay the “PCR-Fluo-ASXL1-FA.”

Results

First, we evaluated the efficiency of our approach compared to NGS and Sanger. We showed that “PCR-Fluo-ASXL1-FA” could detect all insertional mutations of ASXL1 located on its area, with a high sensitivity (1.5%). Then, we have illustrated the interest of this technique by three concrete cases.

Discussion

In summary, we have established a fragment analysis approach, which can detect most ASXL1 mutations, in particular the c.1934dupG, in a sensitive, fast and inexpensive manner. We therefore recommend the synchronous use of this method with NGS, to ensure complete detection of all clinically relevant ASXL1 mutations in patients suffering with myeloid neoplasms.

DATA AVAILABILITY STATEMENT

The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.